Altogether, our results show that setanaxib allows targeting TGF-β pro-tumorigenic actions mediated by CAF, reducing tumour growth and modulating the TME, and represents a new therapeutic approach against iCCA. This evidence concerns the gene TGFB1 and infantile convulsions and choreoathetosis.